AstraZeneca Plc (AZN,AZN.L) said it submitted new drug application to the U.S. Food and Drug Administration for ticagrelor, an investigational oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndrome, or ACS. The proposed trade name for ticagrelor is BRILINTA, pending approval from the FDA.
The company noted that the submission is based on the results of a comprehensive program, including data from PLATO, the Phase III head-to-head trial comparing ticagrelor plus aspirin with clopidogrel plus aspirin.
Ticagrelor is the first reversibly binding oral P2Y12 adenosine diphosphate, or ADP, receptor antagonist. ADP receptor antagonists inhibit the action of platelets in the blood to prevent platelets from sticking together, thereby reducing recurrent thrombotic events.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.